Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Trading Arrangement: Trading Arrangement [Axis] Asset Acquisition [Table] Asset Acquisition [Table] Title of 12(b) Security Title of 12(b) Security Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Document Fiscal Year Focus Document Fiscal Year Focus Adjustment to Compensation, Amount Adjustment to Compensation Amount Financial Instrument [Axis] Financial Instrument [Axis] Customer [Axis] Customer [Axis] Segment Reporting [Abstract] Schedule of Fair Value of Financial Assets Measured on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 248,885 and 262,483 at June 30, 2026, and December 31, 2025, respectively Common Stock, Value, Issued Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Products Derived From Other Compounds Products Derived From Other Compounds [Member] Products Derived From Other Compounds [Member] Restatement Determination Date Restatement Determination Date Ipsen Pharma SAS Ipsen [Member] Ipsen [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Product Or Service Axis [Axis] Product Or Service Axis [Axis] Product Or Service Axis U.S. Treasury and government-sponsored enterprises U.S. Treasury and government-sponsored enterprises US Treasury and Government [Member] Amendment Flag Amendment Flag Collaborative arrangement, maximum aggregate development milestone payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments Current liabilities: Liabilities, Current [Abstract] Selling, general, and administrative Selling, General And Administrative Expense, Excluding Separate Accounts Selling, General And Administrative Expense, Excluding Separate Accounts Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Loss Contingencies [Table] Loss Contingencies [Table] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Accrued collaboration liabilities Accrued Collaboration Liability, Current Accrued Collaboration Liability, Current Entity Address, State or Province Entity Address, State or Province Total Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Gross Unrealized Losses Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Par value (in dollars per share) Common Stock, Par or Stated Value Per Share Rebates Allowance For Product Rebates [Member] Allowance For Product Rebates [Member] Number of awards outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share Repurchase Program [Domain] Share Repurchase Program [Domain] Derivative notional amount Derivative, Notional Amount Basic (in shares) Weighted-average common shares outstanding — basic Weighted Average Number of Shares Outstanding, Basic Share-based Payment Arrangement, Tranche One Share-Based Payment Arrangement, Tranche One [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Loss Contingencies [Line Items] Loss Contingencies [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Number of reportable segments Number of Reportable Segments Income before income taxes Income (Loss) Attributable to Parent, before Tax Total current liabilities Liabilities, Current Revenues recognized for performance obligations satisfied in previous periods Contract with Customer, Performance Obligation Satisfied in Previous Period Collaborative arrangement, maximum aggregate regulatory milestone payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments Concentration Risk [Table] Concentration Risk [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Entity Address, City or Town Entity Address, City or Town Number of awards granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Net product revenues Net product revenues Net product revenues Product [Member] Royalty expense Royalty Expense Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Revenue Revenue from Contract with Customer Benchmark [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Collaboration revenues Collaboration revenues Collaboration [Member] Collaboration [Member] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] License revenues License revenues License revenues License [Member] U.S. UNITED STATES Concentration Risk Type [Axis] Concentration Risk Type [Axis] Recently Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Litigation Case [Axis] Litigation Case [Axis] Municipal bonds Municipal Bonds [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Revenues Revenue from Contract with Customer [Policy Text Block] Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Maturing after one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Document Period End Date Document Period End Date Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net cash provided by investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Security Exchange Name Security Exchange Name Net unrealized gains (losses) on available-for-sale debt securities, tax impact OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax Fiscal Period Fiscal Period, Policy [Policy Text Block] Purchases of marketable securities Payments to Acquire Marketable Securities Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company In an Unrealized Loss Position 12 Months or Greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Segment Reporting Segment Reporting, Policy [Policy Text Block] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] NET INCOME PER SHARE Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Reduction in share reserve after stock option or stock appreciation award (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award Share-based Compensation Arrangement by Share-based Payment Award, Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award Proceeds from maturities and sales of marketable securities Proceeds from Sale and Maturity of Marketable Securities Net income per share: Earnings Per Share [Abstract] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Discounts and allowances Product, Sales Discounts And Allowances [Member] Product, Sales Discounts And Allowances [Member] Total liabilities Liabilities Trading Symbol Trading Symbol Other Customer Credits/Fees and Co-pay Assistance Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member] Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member] Geographical [Domain] Geographical [Domain] Purchases of property, equipment and other, net Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Options, unrecognized stock-based compensation Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Drug discovery Drug Discovery Costs Drug Discovery Costs Company Selected Measure Name Company Selected Measure Name Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Concentration Risk [Line Items] Concentration Risk [Line Items] October 2025 Repurchase Program October 2025 Repurchase Program [Member] October 2025 Repurchase Program Research Collaborations, In-Licensing Arrangements and Other Business Development Activities Research Collaborations, In-Licensing Arrangements and Other Business Development Activities [Member] Research Collaborations, In-Licensing Arrangements and Other Business Development Activities Amortized Cost Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis Affiliates of Cencora, Inc. Affiliates Of Cencora, Inc [Member] Affiliates Of Cencora, Inc. (formerly Amerisource Bergen Corporation) [Member] Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Affiliates of McKesson Corporation Affiliates of McKesson Corporation [Member] Affiliates of McKesson Corporation [Member] Diluted (in shares) Weighted-average common shares outstanding — diluted Weighted Average Number of Shares Outstanding, Diluted Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Commercial paper Commercial Paper [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Vesting award percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Dilutive securities Weighted Average Number of Shares Outstanding, Diluted, Adjustment Affiliates of Optum Specialty Pharmacy Affiliates of Optum Specialty Pharmacy [Member] Affiliates of Optum Specialty Pharmacy [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Amended And Restated 2017 Equity Incentive Plan Amended And Restated 2017 Equity Incentive Plan [Member] Amended And Restated 2017 Equity Incentive Plan Fair Value Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Schedule of Concentration Risks Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Non-cash lease expense Noncash Lease Expense Noncash Lease Expense Effective income tax rate (as percent) Effective Income Tax Rate Reconciliation, Percent Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Gross Unrealized Gains Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax Debt securities available-for-sale: Debt Securities, Available-for-Sale [Abstract] Inventory, Current [Table] Inventory, Current [Table] All Executive Categories All Executive Categories [Member] Repurchases of common stock Stock Repurchased and Retired During Period, Value Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Vesting [Domain] Vesting [Domain] Plan Name [Domain] Plan Name [Domain] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Fair Value Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure Schedule of Computation of Basic and Diluted Net Income Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] SEGMENT REPORTING Segment Reporting [Text Block] Expiration Date Trading Arrangement Expiration Date Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Weighted-average common shares outstanding: Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Income Statement Location [Axis] Location, Statement of Income, Balance [Axis] Fair Value Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Common stock Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Shares authorized (in shares) Common Stock, Shares Authorized Numerator: Earnings Per Share Reconciliation [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Accrued compensation and benefits Accrued Employee Benefits, Current Exercise Price Award Exercise Price Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Stock repurchase program, authorized amount Share Repurchase Program, Authorized, Amount Segment Reporting [Line Items] Segment Reporting [Line Items] Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Europe Europe [Member] Contract assets Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent Mary C. Beckerle [Member] Mary C. Beckerle Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity Component [Domain] Equity Component [Domain] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Total operating expenses Costs and Expenses Adoption Date Trading Arrangement Adoption Date Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Organization And Summary Of Significant Policies [Line Items] Organization And Summary Of Significant Policies [Line Items] Organization And Summary Of Significant Policies [Line Items] ASSETS Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate MSN II ANDA MSN II ANDA [Member] MSN II ANDA Cumulative net sales milestone Revenue From Contract With Customer, Commercial Sales Milestone, Net Sales Threshold Revenue From Contract With Customer, Commercial Sales Milestone, Net Sales Threshold Insider Trading Policies and Procedures [Line Items] Options outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Ipsen And Takeda Collaborations Ipsen And Takeda Collaborations [Member] Ipsen And Takeda Collaborations Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Performance-based restricted stock units Performance Shares [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Selling, general and administrative Selling, General and Administrative Expense Revenue from contract with customer, regulatory milestone Revenue From Contract With Customer, Regulatory Milestone Revenue From Contract With Customer, Regulatory Milestone Collaborative Arrangement with Ipsen Collaborative Arrangement with Ipsen [Member] Collaborative Arrangement with Ipsen [Member] Amortized Cost Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost COMETRIQ Cometriq [Member] Cometriq [Member] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Rebates and fees due to customers Customer Refund Liability, Current Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Gross Unrealized Losses Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss Anti-dilutive securities and contingently issuable shares excluded (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of business segments Number of Operating Segments Restricted stock units Restricted Stock Units (RSUs) [Member] Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Entity Central Index Key Entity Central Index Key All Adjustments to Compensation All Adjustments to Compensation [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net cash provided by operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Resulting From Discovery Efforts Resulting From Discovery Efforts [Member] Resulting From Discovery Efforts [Member] Accounts Receivable Accounts Receivable [Member] Income Statement [Abstract] Income Statement [Abstract] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Document Transition Report Document Transition Report Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Operating expenses: Operating Expenses [Abstract] Deferred tax assets, net Deferred Income Tax Assets, Net Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Net revenue from sales milestone Revenue From Contract With Customer, Regulatory Milestone, Net Revenue From Contract With Customer, Regulatory Milestone, Net City Area Code City Area Code Gross product revenues Product, Gross [Member] Product, Gross [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] Schedule of Revenues Disaggregated by Geographic Region Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue [Table Text Block] Balance at December 31, 2025 Balance at June 30, 2026 SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Name Forgone Recovery, Individual Name Gross Unrealized Gains Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Cardinal Health, Inc. Cardinal Health [Member] Cardinal Health Statement [Line Items] Statement [Line Items] Non-current marketable securities Marketable Securities, Noncurrent Total assets Assets Shares issued (in shares) Preferred Stock, Shares Issued Schedule of Allocated Stock-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax STOCKHOLDERS’ EQUITY Share-Based Payment Arrangement [Text Block] PEO PEO [Member] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Total stock-based compensation Total stock-based compensation Share-Based Payment Arrangement, Expense Repurchases of common stock (in shares) Stock Repurchased and Retired During Period, Shares Marketable securities Marketable Securities, Current Other non-current liabilities Other Liabilities, Noncurrent Goodwill Goodwill Amendment and restatement increase (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Number of investments in an unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Weighted average grant date fair value, awarded (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Maximum potential to vest Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Weighted Average Contractual Term Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Weighted Average Contractual Term [Abstract] Maturing in one year or less Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Percent of royalty on net sale Collaboration Agreement, Percent Of Royalty On Net Sale Collaboration Agreement, Percent Of Royalty On Net Sale Accumulated Deficit Retained Earnings [Member] Non-current operating lease liabilities Operating Lease, Liability, Noncurrent Money market funds Money market funds Money Market Funds [Member] Contract revenue recognized, including revenue from deferred revenue beginning balance Contract With Customer, Liability, Including New Contract Revenue, Recognized Contract With Customer, Liability, Including New Contract Revenue, Recognized Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Number of products that entered in the commercial marketplace Number Of Products In Commercial Market Number Of Products In Commercial Market Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $475, $197, $1,622 and $(786), respectively OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Diluted (in dollars per share) Net income per share — diluted Earnings Per Share, Diluted Entity Current Reporting Status Entity Current Reporting Status Net cash used in financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Collaborative Arrangements with Glaxo Smith Kline Collaborative Arrangements with Glaxo Smith Kline [Member] Collaborative Arrangements with Glaxo Smith Kline Total Shareholder Return Amount Total Shareholder Return Amount Current period Valuation Allowances And Reserves, Additions For Sales In Current Period Valuation Allowances And Reserves, Additions For Sales In Current Period Stock transactions associated with taxes withheld on equity awards Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Provision related to sales made in: Valuation Allowances And Reserves, Additions To Provision [Abstract] Valuation Allowances And Reserves, Additions To Provision [Abstract] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Litigation Case [Domain] Litigation Case [Domain] Prior periods Valuation Allowances And Reserves, Additions For Sales In Prior Period Valuation Allowances And Reserves, Additions For Sales In Prior Period Research and development Research and Development Expense Adjustments to reconcile net income to net cash provided by operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Total revenues Revenues Net product revenues Revenue from Contract with Customer, Excluding Assessed Tax Property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Financial Instruments [Domain] Financial Instruments [Domain] INVENTORY Inventory Disclosure [Text Block] Repurchases of common stock Stock Repurchased During Period, Value Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Underlying Securities Award Underlying Securities Amount REVENUES Revenue from Contract with Customer [Text Block] Proceeds from issuance of common stock under the equity incentive plan and stock purchase plan Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Inventory Increase (Decrease) in Inventories Right-of-use assets and other non-current assets Operating Lease, Right-Of-Use Asset And Other Non-Current Assets Operating Lease, Right-Of-Use Asset And Other Non-Current Assets Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Segment Reporting [Table] Segment Reporting [Table] Number of contract Derivative, Number of Instruments Held Cash Cash [Member] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] In an Unrealized Loss Position Less than 12 Months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Development Development Expenses Development Expenses Income from operations Operating Income (Loss) Collaboration services revenues Collaboration services revenues Collaboration services revenues Service [Member] Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Current Fiscal Year End Date Current Fiscal Year End Date Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Repurchases of common stock (in shares) Stock Repurchased During Period, Shares Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Issuance of common stock under the equity incentive plan and stock purchase plan Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity Investments Classified by Contractual Maturity Date [Table Text Block] Corporate bonds Corporate bonds Corporate Bond Securities [Member] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Shares issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Finished goods Inventory, Finished Goods, Gross Product Or Service Axis [Domain] Product Or Service Axis [Domain] Product Or Service Axis [Domain] Allowance for credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss In an Unrealized Loss Position 12 Months or Greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Equity Components [Axis] Equity Components [Axis] Trade receivables, net Increase (Decrease) in Accounts Receivable Product and Service [Domain] Product and Service [Domain] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Entity Interactive Data Current Entity Interactive Data Current Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity Small Business Entity Small Business CABOMETYX Cabometyx [Member] Cabometyx [Member] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Termination Date Trading Arrangement Termination Date Revenue from contract with customer, commercial sales milestone Revenue From Contract With Customer, Commercial Sales Milestone Revenue From Contract With Customer, Commercial Sales Milestone Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Other current liabilities Other Liabilities, Current Document Type Document Type Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value as of Grant Date Award Grant Date Fair Value Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Number of patents allegedly infringed Loss Contingency, Patents Allegedly Infringed, Number Acquired in-process research and development technology Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Stock repurchase program, remaining authorized repurchase amount Share Repurchase Program, Remaining Authorized, Amount Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block] Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block] Arrangement Duration Trading Arrangement Duration Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Accrued clinical trial liabilities Accrued Clinical Liabilities, Current Accrued Clinical Liabilities, Current Local Phone Number Local Phone Number Non-current portion Contract with Customer, Liability, Noncurrent Work in process Inventory, Work in Process, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name In an Unrealized Loss Position Less than 12 Months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Commitments and contingencies (Note 11) Commitments and Contingencies Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] Chargebacks, Discounts for Prompt Payment and Other Chargebacks And Discounts For Prompt Payment [Member] Chargebacks And Discounts For Prompt Payment [Member] Award vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Acquired in-process research and development technology Payments to Acquire in Process Research and Development Contract liabilities: Accounts Payable and Accrued Liabilities [Abstract] Organization And Summary Of Significant Policies [Table] Organization And Summary Of Significant Policies [Table] Organization And Summary Of Significant Policies [Table] Inventory Inventory, Net Award Type [Domain] Award Type [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Weighted average grant date fair value, awarded (in dollars per share) Share Price PEO Name PEO Name Geographical [Axis] Geographical [Axis] Accrued collaboration liabilities Increase (Decrease) in Accrued Liabilities Total contract liabilities Contract with Customer, Liability Other segment items Segment Reporting, Other Segment Item, Amount Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block] Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Payments and customer credits issued SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Schedule of Collaborative Revenues Under Collaboration and License Agreement Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Collaborative Arrangement with Takeda Collaborative Arrangement with Takeda [Member] Collaborative Arrangement with Takeda [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Accounts payable and other liabilities Increase (Decrease) in Accounts Payable Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Collaborative Arrangements with Royalty Pharma Collaborative Arrangements with Royalty Pharma [Member] Collaborative Arrangements with Royalty Pharma Employee stock purchase plan Employee Stock [Member] Customer [Domain] Customer [Domain] Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Basic (in dollars per share) Net income per share — basic Earnings Per Share, Basic Raw materials Inventory, Raw Materials, Gross Current portion Contract with Customer, Liability, Current Payments for repurchases of common stock Payments for Repurchase of Common Stock Total current assets Assets, Current Insider Trading Arrangements [Line Items] Award Type [Axis] Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accumulated deficit Retained Earnings (Accumulated Deficit) Product and Service [Axis] Product and Service [Axis] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Stock Common Stock [Member] Fair Value Total debt securities available-for-sale Total debt securities available-for-sale Debt Securities, Available-for-Sale Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Cover [Abstract] Cover [Abstract] Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Derivative Contract [Domain] Derivative Contract [Domain] Percent of total revenues Concentration Risk, Percentage Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Number of lawsuits Loss Contingency, Number Of Lawsuits Consolidated Loss Contingency, Number Of Lawsuits Consolidated Equity Awards Adjustments Equity Awards Adjustments [Member] Gross Unrealized Losses Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES Collaborative Arrangement Disclosure [Text Block] Asset Acquisition [Line Items] Asset Acquisition [Line Items] Total liabilities and stockholders’ equity Liabilities and Equity Interest income Interest income Interest Income, Other Stock options Share-Based Payment Arrangement, Option [Member] Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Plan Name [Axis] Plan Name [Axis] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Tabular List, Table Tabular List [Table Text Block] Vesting [Axis] Vesting [Axis] Additional paid-in-capital Additional Paid in Capital Schedule of Investments by Security Type Unrealized Gain (Loss) on Investments [Table Text Block] Other income (expenses), net Other Nonoperating Income (Expense) Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Name Awards Close in Time to MNPI Disclosures, Individual Name Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Shares authorized (in shares) Preferred Stock, Shares Authorized Trade receivables, net Receivables, Net, Current Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued Preferred Stock, Value, Issued Adjustment to Compensation: Adjustment to Compensation [Axis] Share Repurchase Program [Axis] Share Repurchase Program [Axis] CASH AND MARKETABLE SECURITIES Investment in Debt and Equity Instruments and Cash and Cash Equivalent [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Foreign Exchange Forward Foreign Exchange Forward [Member] Preferred stock Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Inventory [Line Items] Inventory [Line Items] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Total financial assets carried at fair value Assets, Fair Value Disclosure Name Measure Name PROVISION FOR INCOME TAXES Income Tax Disclosure [Text Block] Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Reportable Segment Reportable Segment [Member] Reportable Segment Other, net Other Noncash Income (Expense) Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Additional Paid-in Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Total Debt Securities, Available-for-Sale, Unrealized Loss Position Interest receivable Interest Receivable Name Trading Arrangement, Individual Name Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Cash and cash equivalents Cash and Cash Equivalent Accredo Health Group, Inc. Accredo Health, Incorporated [Member] Accredo Health, Incorporated SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Company Selected Measure Amount Company Selected Measure Amount Affiliates of CVS Health Corporation Affiliates of CVS Health Corporation [Member] Affiliates of CVS Health Corporation [Member] Schedule of Segment and Consolidated Net Income, Including Significant Segment Expenses Segment Reporting, Reconciliation of Profit (Loss) by Segment to Consolidated [Table Text Block] Less: Segment Reporting, Reconciliation of Other Item by Segment to Consolidated [Abstract] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Total Inventory, Gross Issuance of common stock under the equity incentive plans and stock purchase plan (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Current assets: Assets, Current [Abstract] Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments Non-PEO NEO Non-PEO NEO [Member] Entity Address, Address Line One Entity Address, Address Line One Provision for income taxes Income Tax Expense (Benefit) Customer Concentration Risk Customer Concentration Risk [Member] Cost of goods sold Cost of goods sold Cost of Product and Service Sold SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Award Timing Method Award Timing Method [Text Block] Basis of Consolidation Consolidation, Policy [Policy Text Block] Net decrease in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Segment and consolidated net income Net income Net income Net Income (Loss) Attributable to Parent Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Balance Sheet Location [Axis] Location, Statement of Financial Position, Balance [Axis] Statement [Table] Statement [Table] Share-based Payment Arrangement, Tranche Two Share-Based Payment Arrangement, Tranche Two [Member] Restatement Determination Date: Restatement Determination Date [Axis] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Certificates of deposit Certificates of deposit Certificates of Deposit [Member] Derivative term of contract Derivative, Contract Term 2026 TSR-based RSUs TSR-Based Restricted Stock Units [Member] TSR-Based Restricted Stock Units Schedule of Other Assets and Other Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Japan JAPAN Share-based Payment Arrangement Share-Based Payment Arrangement [Member] Revenues: Revenues [Abstract] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block]